Market Cap (In TWD)
6.86 Billion
Revenue (In TWD)
314.5 Million
Net Income (In TWD)
8.45 Million
Avg. Volume
288.4 Thousand
- Currency
- TWD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 48.25-125.5
- PE
- -
- EPS
- -
- Beta Value
- 0.553
- ISIN
- TW0006875008
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Pei Ken Ph.D.
- Employee Count
- -
- Website
- https://www.pharmosa.com.tw
- Ipo Date
- 2022-02-22
- Details
- Pharmosa Biopharm Inc., a biotechnology company, focuses on developing drugs in Taiwan. It is developing L606, an inhalation/device combination for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; and L608, an inhalation/device combination for the treatment of pulmonary vascular disease. The company was formerly known as Pharmosa Limited and changed its name to Pharmosa Biopharm Inc. in October 2016. Pharmosa Biopharm Inc. was founded in 2000 and is headquartered in Taipei City, Taiwan.
More Stocks
-
3131
-
2062
-
4106Apex Medical Corp.
4106
-
4760Alpha Co., Ltd.
4760
-
6657
-
WISEWise Group AB (publ)
WISE
-
5272
-
9845Parker Corporation
9845